1. Home
  2. COUR vs SPRY Comparison

COUR vs SPRY Comparison

Compare COUR & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COUR
  • SPRY
  • Stock Information
  • Founded
  • COUR 2012
  • SPRY 2015
  • Country
  • COUR United States
  • SPRY United States
  • Employees
  • COUR N/A
  • SPRY N/A
  • Industry
  • COUR Computer Software: Prepackaged Software
  • SPRY Biotechnology: Pharmaceutical Preparations
  • Sector
  • COUR Technology
  • SPRY Health Care
  • Exchange
  • COUR Nasdaq
  • SPRY Nasdaq
  • Market Cap
  • COUR 1.3B
  • SPRY 1.1B
  • IPO Year
  • COUR 2021
  • SPRY N/A
  • Fundamental
  • Price
  • COUR $8.04
  • SPRY $11.24
  • Analyst Decision
  • COUR Buy
  • SPRY Strong Buy
  • Analyst Count
  • COUR 14
  • SPRY 4
  • Target Price
  • COUR $10.77
  • SPRY $26.00
  • AVG Volume (30 Days)
  • COUR 2.2M
  • SPRY 1.2M
  • Earning Date
  • COUR 01-30-2025
  • SPRY 03-20-2025
  • Dividend Yield
  • COUR N/A
  • SPRY N/A
  • EPS Growth
  • COUR N/A
  • SPRY N/A
  • EPS
  • COUR N/A
  • SPRY N/A
  • Revenue
  • COUR $694,674,000.00
  • SPRY $2,568,000.00
  • Revenue This Year
  • COUR $5.97
  • SPRY $68,783.34
  • Revenue Next Year
  • COUR $5.31
  • SPRY $503.87
  • P/E Ratio
  • COUR N/A
  • SPRY N/A
  • Revenue Growth
  • COUR 9.27
  • SPRY 8460.00
  • 52 Week Low
  • COUR $6.29
  • SPRY $7.55
  • 52 Week High
  • COUR $16.74
  • SPRY $18.51
  • Technical
  • Relative Strength Index (RSI)
  • COUR 45.91
  • SPRY 37.72
  • Support Level
  • COUR $7.78
  • SPRY $11.58
  • Resistance Level
  • COUR $9.02
  • SPRY $12.43
  • Average True Range (ATR)
  • COUR 0.37
  • SPRY 0.72
  • MACD
  • COUR 0.01
  • SPRY -0.14
  • Stochastic Oscillator
  • COUR 41.23
  • SPRY 0.53

About COUR Coursera Inc.

Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Share on Social Networks: